The studies discussed in this literature review are suggestive of greater efficacy and benefits via the SC route of EPO administration over the IV route in most cases of chronic kidney disease, keeping in view the factors mentioned earlier - drug costs, efficacy, convenience, dosage frequency, stage of CKD, type of ESA used, and drug safety and tolerability. Here, EPO is linked to chronic kidney disease.